Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Antibody Responses in Children With Multisystem Inflammatory Syndrome in Children (MIS-C) and Mild and Severe Coronavirus Disease 2019 (COVID-19)

  1. Elizabeth M Anderson
  2. Caroline Diorio
  3. Eileen C Goodwin
  4. Kevin O McNerney
  5. Madison E Weirick
  6. Sigrid Gouma
  7. Marcus J Bolton
  8. Claudia P Arevalo
  9. Julie Chase
  10. Philip Hicks
  11. Tomaz B Manzoni
  12. Amy E Baxter
  13. Kurt P Andrea
  14. Chakkapong Burudpakdee
  15. Jessica H Lee
  16. Laura A Vella
  17. Sarah E Henrickson
  18. Rebecca M Harris
  19. E John Wherry
  20. Paul Bates
  21. Hamid Bassiri
  22. Edward M Behrens
  23. David T Teachey
  24. Scott E Hensley

Reviewed by

Read the full article See related articles

Listed in

Log in to save this article

Abstract

Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) antibody responses in children remain poorly characterized. Here, we show that pediatric patients with multisystem inflammatory syndrome in children (MIS-C) possess higher SARS-CoV-2 spike immunoglobulin G (IgG) titers compared with those with severe coronavirus disease 2019, likely reflecting a longer time since the onset of infection in MIS-C patients.

Article activity feed

  1. Version published to 10.1093/jpids/piaa161
  2. ScreenIT

    SciScore for 10.1101/2020.08.17.20176552: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: This study was approved by the institutional review board at the Children’s Hospital of Philadelphia.
    Consent: Verbal informed consent was obtained from patients or their guardians in accordance with the Declaration of Helsinki.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Antibodies
    SentencesResources
    Quantification of SARS-CoV-2 serum antibody titers: Serum IgG, IgM, and IgA antibody titers against SARS-CoV-2 antigens were quantified by enzyme-linked immunosorbent assays (ELISA) as previously described (13).
    IgA
    suggested: None
    SARS-CoV-2
    suggested: None
    Also included in this mixture to neutralize any potential VSV-G carryover virus was 1E9F9, a mouse anti-VSV Indiana G, at a concentration of 600 ng/ml (Cat#Ab01402-2.0, Absolute Antibody, Oxford, UK).
    anti-VSV
    suggested: None
    Experimental Models: Cell Lines
    SentencesResources
    Production of VSV pseudotypes with SARS-CoV-2 S for neutralization assays: 293T cells plated 24 hours previously at 5 × 106 cells per 10 cm dish were transfected using calcium phosphate with 35μg of pCG1 SARS-CoV S delta18 expression plasmid encoding a codon optimized SARS-CoV S gene with an 18 residue truncation in the cytoplasmic tail (kindly provided by Stefan Pohlmann (German Primate Center, Göttingen, DE).
    293T
    suggested: None
    Vero E6 cells stably expressing TMPRSS2 were seeded in 100 μl at 2.5×104 cells/well in a 96 well collagen coated plate.
    Vero E6
    suggested: None
    The serum-virus mixture was then used to replace the media on VeroE6 TMPRSS2 cells.
    VeroE6 TMPRSS2
    suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)
    Software and Algorithms
    SentencesResources
    Statistical analyses were performed using Prism version 8 (GraphPad Software, San Diego CA).
    Prism
    suggested: (PRISM, RRID:SCR_005375)
    GraphPad
    suggested: (GraphPad Prism, RRID:SCR_002798)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

    Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

    Results from TrialIdentifier: No clinical trial numbers were referenced.

    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

    Results from JetFighter: We did not find any issues relating to colormaps.

    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.

  3. Version published to 10.1101/2020.08.17.20176552v1 on medRxiv